Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease
Alzheimer Disease
About this trial
This is an interventional treatment trial for Alzheimer Disease
Eligibility Criteria
Inclusion Criteria: Patient presents with Alzheimer's Disease based on clinical history. Patient must have a Mini Mental Status Score between 10 and 26. Patient must have a reliable caregiver in frequent or daily contact with the patient. Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months. Exclusion Criteria: Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease. Patients who have a history in the past 5 years or any current evidence of major psychiatric illness. Patients who have narrow angle glaucoma. Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.
Sites / Locations
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician